Scenic Biotech - Company Research Report
Company Overview
Name, Mission of the Company
- Name: Scenic Biotech
- Mission: To unlock the groundbreaking science of genetic modifiers and develop disease-modifying therapies to offer hope for patients with devastating conditions, including neuro- and metabolic diseases.
Founding Information
- Founded: 2017
- Founded By: Spin-out of the Netherlands Cancer Institute and Oxford University
Key People
- CEO & Executive Director: Oscar Izeboud, PhD
- CMO: Jens Würthner, MD, PhD
- VP Legal: Margot Hoppe
- VP Development: Annette Galler, PhD
- Head People & Culture: Carola Jongerius
Board of Directors
- Chairman: Philippe Dro
- CEO & Executive Director: Oscar Izeboud, PhD
- Independent Non-Executive Director: Ben Machielse, PhD
- Non-Executive Director: Edward van Wezel, Simone Botti, PhD, Stéphane Verdood, Michael Wacker, Stephan Christgau, PhD
- Founder & Board Observer: Prof. Thijn Brummelkamp
- Board Observer: Nick Dixon-Clegg
Headquarters
- Amsterdam Office: Science Park 301, 1098 XH Amsterdam, The Netherlands
- New York Office: 136 Madison Avenue, 6th Floor, Manhattan, New York, NY 10016, USA
Number of Employees
No information is available
Revenue
No information is available
Company Recognition
- Known for: Discovery of genetic modifiers to develop transformative therapeutics, especially focused on genetic disorders and severe diseases.
Products
Cell-Seq Platform
- Description: Uses haploid human cells to discover genetic modifiers. These cells carry a single copy of every gene. Targets can be isolated via fluorescent labeling and FACS sorting followed by DNA sequencing.
- Key Features:
- Comprehensive overview of genetic modifiers.
- Generation of high-resolution “disease maps”.
- Unlocking disease-specific genetic modifiers and novel biological pathways.
Pipeline
Neuro and Metabolic Diseases
1. Niemann Pick Type C (NPC):
- Target: Small-molecule inhibitors for NPC1 gene mutations.
- Status: Preclinical studies ongoing.
2. Galactosemia:
- Target: Small-molecule inhibitor against GALK.
- Status: Preclinical studies initiated.
3. Other Programs:
- X-ALD, Barth Syndrome, HSAN1, MacTel2.
Immunology
1. SC-2882 for Immuno-oncology:
- Target: QPCTL, inhibiting CD47-SIRPα checkpoint.
- Status: Completing IND-enabling studies.
- Mechanism: Modifying chemokines to increase anti-tumor macrophage presence.
Recent Developments
New Partnerships
- Research Collaboration with Bristol Myers Squibb: Investigating new potential partners to advance pipeline.
- Cooperative Research with NIH: For Niemann-Pick Type C disease.
Recent Product and Feature Launches
- QPCTL Inhibitor (SC-2882): Presented positive preclinical data showcasing potential as a treatment for diffuse large B-cell lymphoma (DLBCL).
- Partnership with Barth Syndrome Foundation: Exploring genetic modifiers to find treatments for Barth Syndrome.
Management and Board Expansion
- Ben Machielse Appointed to Board of Directors: Industry veteran with extensive drug development experience.
- Jens Würthner Appointed as CMO: Bringing substantial clinical development expertise.
Contact Information
- Email: info@scenicbiotech.com
- Phone: +31 20 7059 990 (Amsterdam), +1 646 722 3322 (New York)
Further details and inquiries can be directed to the company's main contact points as listed above.